Moderna's Experimental Flu Vaccine Outperforms Competitors in Trial

Moderna's flu vaccine showed stronger immune response in late-stage trials, leading to plans for approval and a combination Covid/flu shot. The vaccine was 26.6% more effective than competitors, especially in older adults. Moderna aims to submit applications later this year, pending regulatory approval.